BIOT 6-K
Instinct Bio Technical Co Holdings Inc. (BIOT)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2026
Commission File Number: 001-43415
Instinct Bio Technical Company Holdings Inc.
(Registrant’s Name)
3rd Floor West Side Gotanda bldg.
6-2-7 Nishi Gotanda, Shinagawa-ku,
Tokyo 1410031, Japan
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):¨
Information Contained in this Form 6-K Report
On August 10, 2026, Instinct Bio Technical Company Holdings Inc. (the “Company”) announced it had entered into a cooperation agreement with PT Parva Candela, an Indonesian cosmetics manufacturer and distributor, in respect of the joint development of Indonesia’s cosmetics and personal care market. A copy of the press release is attached hereto as Exhibit 99.1.
The information contained in this Report on Form 6-K, including Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
INDEX TO EXHIBIT
| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release dated August 10, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Instinct Bio Technical Company Holdings Inc. | ||
|---|---|---|
| Date: August 10, 2026 | By: | /s/ Tomoki Nagano |
| Name: | Tomoki Nagano | |
| Title: | Chief Executive Officer and Director |
Exhibit 99.1
Instinct Bio Announces Strategic Collaborationwith PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
NEW YORK, NY and TOKYO, JAPAN - August 10, 2026
- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) (“Instinct Bio” or the “Company”) today announced a cooperation agreement with PT PARVA CANDELA ("PARVA"), an Indonesian cosmetics manufacturer and distributor, to jointly develop Indonesia’s cosmetics and personal care market under a "Made in Indonesia, Powered by Japanese Formulation Expertise" concept.
Key Facts
| • | Route to market: PARVA is affiliated with DELTASPA Group, a spa chain<br>operating approximately 25 locations across Indonesia, providing an established distribution network from day one. |
|---|---|
| • | Proven sales playbook: Products from PARVA’s facility will<br>be sold using the B2B and offline & online B2C sales and sales management methods Instinct Bio has built over many years in Japan,<br>supporting rapid establishment of a sales base in Indonesia. |
| --- | --- |
| • | Local manufacturing: The parties intend to use PARVA’s existing<br>BPOM-recognized facility, manufacturing to GMP standards and Japanese GVP/GQP quality frameworks. |
| --- | --- |
| • | Halal readiness: Products will be manufactured to comply with Indonesia’s<br>regulatory requirements, including halal certification for cosmetics circulating in Indonesia, allowing the collaboration to respond proactively<br>to market demand. |
| --- | --- |
| • | Intellectual property: Instinct Bio retains ownership of proprietary<br>ingredients and formulations, granting limited licenses. |
| --- | --- |
| • | Revenue streams: In addition to a 50% profit share, Instinct Bio<br>expects revenue from proprietary ingredient supply, formulation royalties, and brand licensing fees for its GENRÊVER and HAKUA brands. |
| --- | --- |
| • | Indonesia platform: The collaboration is the third component of the<br>Company’s organic growth strategy, following the integrated GENRÊVER CLINIC announcement (July 29, 2026) and the collaboration<br>with Invitrx Therapeutics, Inc. (July 30, 2026). |
| --- | --- |
| • | Market Context: Indonesia’s beauty and personal care market<br>is estimated at approximately US$10.5 billion in 2026, growing approximately 5.5% annually (source: Statista Market Insights, Beauty &<br>Personal Care — Indonesia). |
| --- | --- |
"Indonesia is one of the world’s most popular markets, and this venture gives us what new entrants rarely have on day one. Through this collaboration, we hope to bring many smiles to consumers in Indonesia," said Tomoki Nagano, Chairman and CEO of Instinct Bio.
Full announcement: https://instinct-biot.com/news/.
About Instinct Bio
Instinct Bio Technical Company Holdings Inc. is a Cayman Islands-incorporated holding company with Japan-originated businesses spanning regenerative medicine R&D, sourcing, manufacturing, cosmetics, wellness and consumer brands.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. federal securities laws, including statements regarding the collaboration and the Company’s Indonesia strategy. Such statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including those described under "Risk Factors" in the Company’s filings with the U.S. Securities and Exchange Commission, available at www.sec.gov. There can be no assurance that the collaboration will achieve any particular commercial result or that a joint venture company will be formed. Forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to update them except as required by applicable law.
Contact
Email: [email protected]
Website: https://instinct-biot.com/